Fair Value Measurements - Additional Information (Detail) - USD ($)		6 Months Ended	12 Months Ended
	May 04, 2021	Jun. 30, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value assets, Level 1 to Level 2 transfers		$ 0	$ 0
Fair value assets, Level 2 to Level 1 transfers		0	0
Fair value liabilities, Level 1 to Level 2 transfers		0	0
Fair value liabilities, Level 2 to Level 1 transfers		0	0
Fair value assets, transfers into Level 3		0	0
Fair value assets, transfers out of Level 3		0	0
Fair value liabilities, transfers into Level 3		0	0
Fair value liabilities, transfers out of Level 3		$ 0	$ 0
Merger Agreement | Kuur Therapeutics, Inc.
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Percentage of milestones payment based on probability of occurrence		40.40%
Merger Agreement | Kuur Therapeutics, Inc. | Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total undiscounted amount of the milestone payments payable	$ 115,000,000.0
Contingent consideration regulatory milestones expected to occur	2027
Percentage of estimated incremental borrowing rate		20.40%
Merger Agreement | Kuur Therapeutics, Inc. | Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration regulatory milestones expected to occur	2023
Percentage of estimated incremental borrowing rate		20.10%
Pharma Essentia | OTC | Taiwan | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of shares owned by company		68,000	68,000